FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline <i>BRCA</i>-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of ChemotherapyGeoffrey Kim, Richard Pazdur, Todd R. Palmby et al.|Clinical Cancer Research|2015Cited by 532
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based ChemotherapyGwynn Ison, Richard Pazdur, Lynn Howie et al.|Clinical Cancer Research|2018Cited by 133
FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These DrugsGwynn Ison, Richard Pazdur, Julia A. Beaver et al.|Clinical Cancer Research|2016Cited by 80
U.S. FDA Drug Approvals for Breast Cancer: A Decade in ReviewShaily Arora, Julia A. Beaver, Preeti Narayan et al.|Clinical Cancer Research|2021Cited by 73
U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in ReviewShaily Arora, Julia A. Beaver, Preeti Narayan et al.|Clinical Cancer Research|2021Cited by 23